Market Overview

BMO Trims Apple Watch Estimates, Boosts iPhone View


In a report published Friday, BMO Capital analyst Keith Bachman maintained an Outperform rating and price target of $145 on Apple Inc. (NASDAQ: AAPL), while raising the iPhone estimates and lowering the Apple Watch estimates.

For FY2016, the iPhone estimate was raised by 3.5 million to 233 million units, while the Apple Watch estimate was lowered by 3 million to 27.5 million units. The iPhone estimate for the June 2015 quarter was also raised.

"We believe the iPhone installed base will be well over 500 million by the end of CY2015. Therefore, we believe that upgrades should contribute about two-thirds of iPhone shipments in CY2016," Bachman elaborated.

The analyst believes that the company would need to generate about a third of the iPhone users as new users to be able to meet the CY2016 estimate, with a large number coming from the emerging markets or converts in existing markets.

In addition, the analyst believes that the iPhone installed base would reach 500 million by the end of 2015. This means that upgrades would account for two-thirds of the iPhone units sold in CY2016.

"[W]e think ongoing growth in iPhones, and aggressive capital allocation, can push the shares higher," Bachman added.

Latest Ratings for AAPL

Oct 2019MaintainsOutperform
Oct 2019MaintainsBuy
Oct 2019MaintainsOutperform

View More Analyst Ratings for AAPL
View the Latest Analyst Ratings

Posted-In: Apple Watch BMO Capital Markets Keith Bachman VetrAnalyst Color Reiteration Analyst Ratings


Related Articles (AAPL)

View Comments and Join the Discussion!

Latest Ratings

NXTCBank of AmericaReiterates89.0
RNRJP MorganAssumes173.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Cowen On Biogen: View June 22 Aducanumab Presentation As 'having the potential to substantially alter perceptions of the probability of ph III success and be worth +/- $50 to BIIB'

5 NASDAQ Utilities Stocks With The Highest ROA